NCT03444012 is a clinical trial of ticagrelor 90 mg in ACS (Acute Coronary Syndrome), sponsored by AstraZeneca.

Who is sponsoring NCT03444012?

NCT03444012 is sponsored by AstraZeneca.

What drugs are being tested in NCT03444012?

Interventions in NCT03444012: ticagrelor 90 mg.

What condition does NCT03444012 study?

NCT03444012 studies ACS (Acute Coronary Syndrome).

Is NCT03444012 still recruiting?

NCT03444012 is currently completed. Last updated 7 August 2020.

Last reviewed 2020-08-07 · How we verify

NCT03444012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ADHERE-S (NIS Brilique)

Completed Last updated 7 August 2020

What this trial tests

trial testing ticagrelor 90 mg in ACS (Acute Coronary Syndrome) in 269 participants. Completed in 13 August 2019.

Timeline

5 March 2018

Primary endpoint
13 August 2019

13 August 2019

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	269
Start date	5 March 2018
Primary completion	13 August 2019
Estimated completion	13 August 2019
Sites	9 locations across Serbia

Drugs / interventions tested

ticagrelor 90 mg — full drug profile →

Conditions studied

ACS (Acute Coronary Syndrome) — all drugs for ACS (Acute Coronary Syndrome) →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with ACS (Acute Coronary Syndrome). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ACS (Acute Coronary Syndrome)

Currently open trials in the same condition.

NCT07231835 — Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons · recruiting
NCT07096973 — Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery · recruiting
NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03444012 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 7 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03444012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing